Hormone Resistant Prostate Cancer Terminated Phase 2 Trials for Orteronel (DB12066)

Also known as: Hormone-Resistant Prostate Cancer

IndicationStatusPhase
DBCOND0038482 (Hormone Resistant Prostate Cancer)Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01866423Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate CancerTreatment